Drug Trial Radar · NCT06511739
A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients
Last checked: Nov 20, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
144
Planned (sponsor's estimate)
Start
May 27, 2024
Primary completion
Aug 1, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.
Conditions
- Non-segmental Vitiligo
Interventions
SYHX1901Drug
SYHX1901 tablet
placeboDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI)Time frame: At 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials Information Group
Shijiazhuang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.